Drug Profile
CSJ 148
Alternative Names: CSJ148; LJP-53; LJP-538; LJP-538/LJP-539; LJP539Latest Information Update: 24 Oct 2018
Price :
$50
*
At a glance
- Originator Humabs BioMed
- Developer Novartis
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 24 Oct 2018 No development reported - Phase-I/II for Cytomegalovirus infections prevention in Belgium, USA, Germany, South Korea, Singapore, Singapore, Taiwan (IV)
- 23 Aug 2018 Novartis Pharmaceuticals withdraws a phase II trial prior to enrolment based upon company's decision for Cytomegalovirus infections (Prevention) in Germany (IV) (EudraCT2017-002047-15)
- 20 Dec 2017 Novartis Pharmaceuticals plans a phase II trial for Cytomegalovirus infections (Prevention) in 2018 (IV) (EudraCT2017-002047-15) (NCT03369912)